Skip to main content
All lobbying filings

TIBER CREEK GROUP

TIBER CREEK GROUP filed a Q4 report for JAZZ PHARMACEUTICALS on January 17, 2026, reporting $50,000 in lobbying income.

Lobbying for JAZZ PHARMACEUTICALS · ​Biopharmaceutical company.

All filings by TIBER CREEK GROUP · Everything JAZZ PHARMACEUTICALS has reported

 Filing · LD-2 quarterly report Q4 report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 17, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
California

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Health Issues

Issues related to the FDA and Health and Human Services pertaining to CBD policies; Issues related to the regulation of intoxicating hemp.

Medical/Disease Research/Clinical Labs

Issues related to cannabis research; Issues related to the FDA; Issues related to cannabis research at Health and Human Services.

Budget/Appropriations

Issues related to FDA enforcement of non-FDA approved, cannabis derived CBD products in H.R. 4121 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to the Ag/FDA amendment - technical correction to hemp in H.R. 4121 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to intoxicating hemp products.

 Bills named in this filing 1
  • H.R. 4121
    Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem